Physician profile
Michael D Williams
NPI 1750334470
$52,405.93
in general payments reported to CMS, 2019-2025
44 companies · $4,567 in 2025
The $4,567 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $353 · 2021: $1,445 · 2022: $2,516 · 2023: $2,837 · 2024: $40K · 2025: $4,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Food and Beverage: $9,714 · Travel and Lodging: $3,368 · Education: $46.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,400.00 |
| Food and Beverage | $9,714.03 |
| Travel and Lodging | $3,368.27 |
| Education | $46.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $39,542.81 | 2024-2025 | Voquezna |
| Abbvie INC. | $3,130.46 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,580.80 | 2020-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,364.36 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,014.68 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $507.27 | 2019-2025 | |
| Pfizer INC. | $504.68 | 2019-2024 | |
| Celgene Corporation | $498.02 | 2021-2024 | Zeposia |
| Amgen INC. | $389.76 | 2021-2023 | Avsola, Amjevita |
| Nestle Healthcare Nutrition INC. | $383.49 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $350.59 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $313.20 | 2021-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $286.80 | 2019-2024 | Dificid, Zinplava |
| Aimmune Therapeutics, INC. | $275.32 | 2024-2025 | Zenpep, Vowst |
| Celltrion USA INC. | $257.90 | 2024-2025 | Vegzelma, Zymfentra |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $243.06 | 2022-2025 | |
| Organon LLC | $191.38 | 2022-2024 | Renflexis, Hadlima |
| Alkermes, INC. | $185.18 | 2022-2025 | Aristada, Lybalvi |
| Mauna Kea Technologies, INC. | $179.05 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $157.85 | 2021-2024 | Linzess |
| Lilly USA, LLC | $135.77 | 2023-2025 | Omvoh |
| Kerecis Limited | $110.39 | 2020 | |
| Acera Surgical, INC. | $90.02 | 2021 | |
| Medtronic, INC. | $87.92 | 2021 | |
| Ethicon US, LLC | $72.03 | 2019-2023 | Linx Reflux Management System |
| Madrigal Pharmaceuticals | $68.93 | 2025 | Rezdiffra |
| Ucb, INC. | $61.67 | 2019 | |
| Novo Nordisk INC | $61.63 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $60.89 | 2019-2023 | Injectafer |
| Qol Medical, LLC | $58.18 | 2021-2025 | Sucraid |
| Glaxosmithkline, LLC. | $38.72 | 2022 | |
| Fresenius Kabi USA, LLC | $37.38 | 2023 | Idacio, Smoflipid |
| Zimmer Biomet Holdings, INC. | $31.25 | 2021 | |
| Sandoz INC. | $26.61 | 2023-2024 | Hyrimoz |
| Ipsen Biopharmaceuticals, INC | $24.76 | 2025 | Iqirvo |
| Dynavax Technologies Corporation | $22.78 | 2021 | |
| Allergan, INC. | $17.65 | 2020 | |
| Exact Sciences Corporation | $15.37 | 2024 | Cologuard Collection Kit |
| Endo Pharmaceuticals INC. | $14.30 | 2019 | |
| Alfasigma USA, INC. | $13.02 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.